![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, November 16, 2023 1:03:38 AM
IF--They get the FDA approval for the pediatric--those specialists start seeing results in kids/lives saved !!!
You never know with the FDA but then getting approval in adult population should not be any harder than pediatric
Start seeing some older people get off ECMO --come out of sepsis
Start seeing some dialysis patients get off that routine nightmare/expense
Using a plug and play device off the shelf --No one will believe you when you tell them the 60 cent/share story
Recent ICU News
- SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device • GlobeNewswire Inc. • 07/03/2024 12:30:00 PM
- SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology • GlobeNewswire Inc. • 06/11/2024 12:30:00 PM
- SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company • GlobeNewswire Inc. • 06/10/2024 12:30:00 PM
- Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation • GlobeNewswire Inc. • 06/07/2024 12:30:00 PM
- SeaStar Medical Announces 25-for-1 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility • GlobeNewswire Inc. • 05/22/2024 12:30:00 PM
- SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure • GlobeNewswire Inc. • 04/30/2024 12:30:00 PM
- SeaStar Medical Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 04/17/2024 08:00:00 PM
- SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- SeaStar Medical to Restate Financials, Sets Business Update Call for April 17 • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024 • GlobeNewswire Inc. • 03/11/2024 08:05:00 PM
- Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ • GlobeNewswire Inc. • 02/22/2024 12:58:00 PM
- FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury • GlobeNewswire Inc. • 02/22/2024 12:53:00 PM
- SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology • GlobeNewswire Inc. • 02/01/2024 01:30:00 PM
- SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market • GlobeNewswire Inc. • 01/26/2024 01:05:00 PM
- SeaStar Medical Appoints David A. Green as Chief Financial Officer • GlobeNewswire Inc. • 01/11/2024 09:05:00 PM
- SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury • GlobeNewswire Inc. • 12/28/2023 01:30:00 PM
- SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts • GlobeNewswire Inc. • 12/13/2023 01:30:00 PM
- SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 11/14/2023 09:04:00 PM
- Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM